Inovio Reports Promising Data - Analyst Blog

By
A A A

Inovio Pharmaceuticals, Inc. ( INO ) recently announced encouraging data from a phase I study on its influenza vaccine candidate, SynCon. SynCon is being developed as a universal H1N1 vaccine to protect against several prevalent H1N1 influenza strains.

The phase I study, which enrolled 100 healthy volunteers, evaluated SynCon in multiple dosages and constructs. It was found that 60% of the volunteers who received the highest dose (1.8 mg) of SynCon at least twice showed similar response rates to that of a currently approved seasonal influenza vaccine against a currently circulating H1N1 A/California/07/09 strain.  

SynCon has demonstrated encouraging efficacy against several vaccine strains prevalent in the last 100 years including H1N1 A/South Carolina/1/18 strain (so-called 1918 Spanish flu) as well as all the H1N1 strains that were part of the seasonal trivalent inactivated flu vaccines (TIV) since 1986, including, A/Taiwan/1/86, A/Texas/36/91, A/Bayern/07/95, A/Beijing/262/95, A/New Caledonia/20/99, A/Solomon Islands/03/06, A/Brisbane/59/07, and A/California/07/09.

We believe if successfully developed and eventually approved SynCon will revolutionize the influenza vaccine market. Currently approved influenza vaccines include AstraZeneca 's ( AZN ) FluMist Quadrivalent and GlaxoSmithKline 's ( GSK ) Fluarix Quadrivalent. The currently approved quadrivalent vaccines protect from two strains of influenza A and influenza B each.

Inovio Pharma is also developing vaccines targeting the lucrative pandemic influenza subtypes, H5N1 and H7N9. These vaccines are primarily sold to government buyers.

Inovio Pharma, a biopharmaceutical company, carries a Zacks Rank #1 (Strong Buy). Biopharma stocks like UCB ( UCBJF ) appear to be equally attractive. UCB also carries a Zacks Rank #1.



ASTRAZENECA PLC (AZN): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

INOVIO PHARMAC (INO): Free Stock Analysis Report

UCB SA (UCBJF): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , GSK , INO , TIV , UCBJF

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com